Background: Treatment of polymyalgia rheumatica (PMR) can be challenging. The most
efficacious and cost-effective treatment of PMR is some type of glucocorticoid (GC), with …

Background Polymyalgia rheumatica (PMR) treatment is based on low-dose glucocorticoids.
Glucocorticoid-sparing agents have also been tested. Our objective was to systematically …

Importance Few treatments are available for patients with glucocorticoid-dependent
polymyalgia rheumatica. IL-6 antagonists may reduce disease activity in patients with active …

Background Glucocorticoids are the cornerstone treatment of polymyalgia rheumatica (PMR)
but induce adverse events. Objectives To evaluate the efficacy and safety of first-line …

Glucocorticoids are the mainstay of treatment for patients with polymyalgia rheumatica
(PMR) and often produce substantial clinical improvements, but treatment can be …

Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease affecting people aged
50 years or older. PMR usually improves with glucocorticoids (GC), with rapid resolution of …

Objectives Polymyalgia rheumatica (PMR) is a systemic inflammatory disease in the elderly
of unknown etiology. While glucocorticoids are the mainstay of treatment for PMR, various …

Polymyalgia rheumatica (PMR) affects older people, and although glucocorticoids are
effective in treating PMR, they frequently result in side effects. Therefore, we conducted a …

Background: Polymyalgia rheumatica (PMR) responds well to treatment with glucocorticoids,
but high relapse rates during glucocorticoid tapering and adverse events associated with …

Objective We investigated the effectiveness of tocilizumab (an anti-interleukin-6 receptor
antibody) in patients with polymyalgia rheumatica (PMR). Methods We performed a …